Alessio Alogna, Katlyn E Koepp, Michael Sabbah, Jair M Espindola Netto, Michael D Jensen, James L Kirkland, Carolyn S P Lam, Masaru Obokata, Mark C Petrie, Paul M Ridker, Hidemi Sorimachi, Tamara Tchkonia, Adriaan Voors, Margaret M Redfield, Barry A Borlaug
BACKGROUND: Interleukin (IL)-6 is a central inflammatory mediator and potential therapeutic target in heart failure (HF). Prior studies have shown that IL-6 concentrations are elevated in patients with HF, but much fewer data are available in HF with preserved ejection fraction (HFpEF). OBJECTIVES: Determine how IL-6 relates to changes in cardiac function, congestion, body composition, and exercise tolerance in HFpEF. METHODS: Clinical, laboratory, body composition, exercise capacity, physiologic and health status data across 4 National Heart, Lung, and Blood Institute-sponsored trials were analyzed according to the tertiles of IL-6...
July 29, 2023: JACC. Heart Failure